These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26768568)

  • 21. A US Food and Drug Administration perspective on evaluating medical products for Ebola.
    Russek-Cohen E; Rubin D; Price D; Sun W; Cox E; Borio L
    Clin Trials; 2016 Feb; 13(1):105-9. PubMed ID: 26768565
    [No Abstract]   [Full Text] [Related]  

  • 22. Reconsidering the ethical permissibility of the use of unregistered interventions against Ebola virus disease.
    Landry JT; Foreman T; Kekewich M
    Camb Q Healthc Ethics; 2015 Jul; 24(3):366-9. PubMed ID: 26059962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel Ordered Stepped-Wedge Cluster Trial Designs for Detecting Ebola Vaccine Efficacy Using a Spatially Structured Mathematical Model.
    Diakite I; Mooring EQ; Velásquez GE; Murray MB
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004866. PubMed ID: 27509037
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The World after Ebola: An Overview of Ebola Complications, Vaccine Development, Lessons Learned, Financial Losses, and Disease Preparedness.
    Waheed Y; Malik S; Khan M; Najmi MH
    Crit Rev Eukaryot Gene Expr; 2019; 29(1):77-84. PubMed ID: 31002597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vaccine testing. Ebola and beyond.
    Lipsitch M; Eyal N; Halloran ME; Hernán MA; Longini IM; Perencevich EN; Grais RF
    Science; 2015 Apr; 348(6230):46-8. PubMed ID: 25838371
    [No Abstract]   [Full Text] [Related]  

  • 26. Ethical considerations in the conduct of research on therapies for the prevention and treatment of Ebola virus disease in developing countries.
    Folayan MO; Haire BG
    Pan Afr Med J; 2015; 22 Suppl 1(Suppl 1):8. PubMed ID: 26740837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ebola vaccine yields first hopes of clinical efficacy.
    Mullard A
    Nat Rev Drug Discov; 2015 Sep; 14(9):593. PubMed ID: 26323537
    [No Abstract]   [Full Text] [Related]  

  • 28. Leveraging contact network structure in the design of cluster randomized trials.
    Harling G; Wang R; Onnela JP; De Gruttola V
    Clin Trials; 2017 Feb; 14(1):37-47. PubMed ID: 27798376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of a Randomized Controlled Trial for Ebola Virus Disease Medical Countermeasures: PREVAIL II, the Ebola MCM Study.
    Dodd LE; Proschan MA; Neuhaus J; Koopmeiners JS; Neaton J; Beigel JD; Barrett K; Lane HC; Davey RT
    J Infect Dis; 2016 Jun; 213(12):1906-13. PubMed ID: 26908739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Infectious disease. Ebola vaccine: little and late.
    Cohen J
    Science; 2014 Sep; 345(6203):1441-2. PubMed ID: 25237082
    [No Abstract]   [Full Text] [Related]  

  • 31. Immunology of protection from Ebola virus infection.
    Krause PR; Bryant PR; Clark T; Dempsey W; Henchal E; Michael NL; Regules JA; Gruber MF
    Sci Transl Med; 2015 May; 7(286):286ps11. PubMed ID: 25947159
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of Ring Vaccination as Control Strategy for Ebola Virus Disease.
    Kucharski AJ; Eggo RM; Watson CH; Camacho A; Funk S; Edmunds WJ
    Emerg Infect Dis; 2016 Jan; 22(1):105-8. PubMed ID: 26691346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Motivation for participating in phase 1 vaccine trials: Comparison of an influenza and an Ebola randomized controlled trial.
    Cattapan A; Browne K; Halperin DM; Di Castri A; Fullsack P; Graham J; Langley JM; Taylor BA; McNeil SA; Halperin SA
    Vaccine; 2019 Jan; 37(2):289-295. PubMed ID: 30528592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conceptions within misconceptions: Pluralisms in an Ebola vaccine trial in West Africa.
    Alenichev A; Peeters Grietens K; Gerrets R
    Glob Public Health; 2020 Jan; 15(1):13-21. PubMed ID: 31237180
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trial design for evaluating novel treatments during an outbreak of an infectious disease.
    Whitehead J; Olliaro P; Lang T; Horby P
    Clin Trials; 2016 Feb; 13(1):31-8. PubMed ID: 26768556
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interest in an Ebola vaccine among a U.S. national sample during the height of the 2014-2016 Ebola outbreak in West Africa.
    Painter JE; DiClemente RJ; von Fricken ME
    Vaccine; 2017 Jan; 35(4):508-512. PubMed ID: 28040206
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infectious Diseases. Ebola vaccine trials raise ethical issues.
    Cohen J; Kupferschmidt K
    Science; 2014 Oct; 346(6207):289-90. PubMed ID: 25324364
    [No Abstract]   [Full Text] [Related]  

  • 38. Using the Ebola outbreak as an opportunity to educate on vaccine utility.
    Brown B
    J Bioeth Inq; 2014 Dec; 11(4):415-6. PubMed ID: 25421820
    [No Abstract]   [Full Text] [Related]  

  • 39. Health plan.
    Nature; 2015 Jun; 522(7554):5. PubMed ID: 26040857
    [No Abstract]   [Full Text] [Related]  

  • 40. As Ebola epidemic begins to slow, trials of drugs and vaccines speed up.
    Kuehn BM
    JAMA; 2015 Mar; 313(10):1000-2. PubMed ID: 25671623
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.